National collection and expansion of the ground for half a year three varieties of the lowest degree of completion! China Sea, AstraZeneca...

The lowest progress of the, PemeQuse, Giphitetini, Fusimply!recently, Jiangxi Province informed the implementation of the state-organized drug centralized procurement and use of the work, since March, Jiangxi Province every month will announce the first batch of 4 plus 7 national expansion of the province's implementationthe first batch of 4 plus 7 national expansion at the end of 2019 began to implement, the current landing has been six months, the second batch of national harvest landing soon and some varieties affected by the epidemic, so that the first batch of 4 plus 7 expansion of the landing of the situation, perhaps more representative of the 4 plus 7 model extended to the national scope, the actual implementation of the situationSince March this year, Jiangxi Province has been three months in a row to inform the first batch of 25 varieties of 31 standards of the landing situationLooking at the progress of the six months, we have found that the progress of collection varies greatly between different varietiesfirst, the completion of the varieties of Permeyquser, Gifitini, Fusinpuri, Oruniampin is relatively low compared to other products, as of May 31, that is, five months and ten days, 50mg specification of the Pemequse completion progress of 55.34%, is the lowest completion schedule, However, relative to less than 50% of the time, this progress is still reasonable, and, the proportion of the selected varieties accounted for the total quantity of all drugs purchased under the same rules is 95.90%, which belongs to the top three levels in 31 rules, which shows that the province's medical institutions are still in accordance with the requirements of centralized procurement landing work, the proportion of selected varieties in the market is still relatively highThe supplier seise in Jiangxi is Sichuan Huiyu Pharmaceuticals, while the selected companies of Jifitini, Fusinpuri and O Nitrogen are AstraZeneca, Huahai and Haussensecond, Jiangxi Province has 9 varieties in a quarter to complete the total amount of the whole year, and in the fourth and fifth months of collection, respectively, this figure reached 17 and 21, it can be seen that most products completed faster, and can achieve much more than the medical institutions reported procurement volumeAmong them, as of May 31 to complete 2 times the purchase volume of products have five, respectively, left BRasitan, Imatini, right Metomidin, chloratan (50mg), Tinofuwe, of which the highest completion of the left Eablytan, close to 600%, this variety in Jiangxi supplier sending Zhejiang Jingxin Pharmaceuticalin general, as of May 31, Jiangxi Province 31 rules of the province's total procurement volume of the agreed total procurement ratio of 118.56 percent, 21 rules to complete the province's agreed procurement quantity, 6 standards completed 75%, 4 standards completed 50%, many enterprises will be far larger than the agreed purchase volume of the market, of course, this is related to the accuracy of the original medical institutions reportedand the second batch of national collection results from April 11 in Jiangxi Province, as of May 31, in 51 days, 36 rules of the province's total procurement volume accounted for 57.08 percent of the agreed total procurement, 4 product regulations completed the province's agreed procurement quantity, 11 rules to complete the progress of more than 50%, the highest completion progress was 696.92% of Abitron 0.25g and the lowest was 1.99% of The bisloar 2.5mgFrom the drug ratio, the total quantity of 36 product regulations in the province accounted for 84.88 percent of the total quantity of all drugs purchased under the same regulations, according to drug statistics, the highest is 100% of the 5mg of Alysson tan tablets, the lowest is 25.41% of amoxicillin 0.5gAmoxilin in Jiangxi's selected manufacturers for North China Pharmaceuticals, the relatively low proportion of drugs may be related to many enterprises with Amoxilin batch number, pharmaceutical intelligence network data show that the variety of domestic a total of 32 approval information, and Alysson tan film competition pattern is relatively good, only GSK, Huahai, Haussen and Zhengda Sunny four have approval, and domestic manufacturers approved in two yearsAlthough the first two rounds of national collection and completion of the progress exceeded expectations, but in the next national collection, the balance retention policy will greatly affect the medical institutions reported, the industry believes that the past reported less than expected, data distortion in the future or will not be since the 2018 4-7 pilot to two rounds of national collection, the national organization of drug collection policy has been evolving, but the previous case of the selection of products will more or less for the late inclusion of the varieties in the collection to provide a certain precedent for reference But if the industry's health-care balance retention policy is in place, how much is the reference value of these precedents? at present, some provinces are adding some of the non-selected drugs hanging network, June 30, Henan Province on Ntikawe, including 109 drugs were added to the network, July 1, Qinghai Province issued a non-selected drug application hanging network and price adjustment notice As in most provinces, Qinghai is no longer open to over-3 varieties that have been evaluated For eligible non-selected varieties, it is still encouraging the state to centralize the procurement of selected enterprises not selected to supply Qinghai Province in the province's secondary price to the network procurement; and the above-mentioned policy of retaining the health insurance balance, or will greatly change the fate of the unselected varieties the core of this policy is to collect the difference between the cost of drugs after the price reduction and the budget fund paid by medical insurance, will be returned as part of the incentive to public medical institutions, the specific retention ratio by the co-ordination area according to the assessment results of fixed-point medical institutions This will greatly affect the proportion of selected and unselected varieties used by medical institutions the specific assessment content and the national collection and collection of the agreed procurement volume, priority procurement, timely settlement, as well as the control of fees, truthfully reported procurement volume and other circumstances linked The fixed-point medical institutions that fail the examination shall not pay the collected balance to retain funds Does this mean that the unselected variety is completely out of the market? analysts believe that for some of the original research varieties and well-known varieties, especially patients with long-term drug use of the slow-disease varieties, after many years of market education and clinical practice, whether in the doctors or in the patient group have a high eras and recognition, such products still have a market Previous collection in the determination of medical insurance payment standards also give such varieties 2-3 years of adjustment period, these varieties after a certain degree of price reduction may improve accessibility and coverage in addition, from the terminal point of view, there is a view that in different levels of hospitals, the fate of non-secondary varieties will be different, in large-scale triple-A hospitals, due to the large amount of use, the balance of many, so in addition to the original research of the unselected varieties of the chances are slim, and in the second and third terminal, whether the balance is large enough, it is not good to say that medical institutions in the selection of drugs there is still uncertainty from the point of view of product decline, analysts believe that medical institutions will undoubtedly be more inclined to choose products that have achieved significant price cuts, especially in the large budget of medical institutions and products with large price cuts at present, the third round of national collection is in the reporting stage, because this time the balance retention policy breaks through the previous logic, so for pharmaceutical enterprises, according to this policy needs to carefully assess their products and decline, and for medical institutions, the balance retention policy is like a tight spell, gradually put it and the direction of health care to the same position.